Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
Clinical trial NCT00728936 · COMPLETED
Trial details
- NCT number
- NCT00728936
- Sponsor
- Idera Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-09-01
- Primary completion
- 2009-12-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.